SecurityCYTX / Cytori Therapeutics, Inc. (23283K105)
IndustrySurgical and Medical Instruments and Apparatus
Common Stock Shares Outstanding61,600,000 shares (as of 2018-06-30)
Total Insiders17
Total Directors8
Total Officers6

Stock Insider Trading (from SEC Form 4)

Cytori Therapeutics, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

CYTX / Cytori Therapeutics, Inc. insiders include Swissquote Bank SA, Girao Tiago, Thompson Tommy G, LAPOINTE ANTHONY GREGG, and KESTEN STEVEN, HAWRAN PAUL W, HARRIS JOHN DAVID, Naughton Gail K, Hawkins Richard J, HEDRICK MARC H, RICKEY DAVID, MARTELL RON, PostFinance AG Lim Kian Thiam, LYONS GARY A, Marino Mark, HAYDEN JEREMY B., .

Insider Roster

Insider Dir Off 10% Shares Owned
Hawkins Richard J Director
X
HEDRICK MARC H President and CEO
X
Girao Tiago VP & Chief Financial Officer
X
PostFinance AG 10% Owner
X 4,543,086
LYONS GARY A Director
X
Swissquote Bank SA 10% Owner
X 5,328,229
RICKEY DAVID Director
X
Naughton Gail K Director
X
HARRIS JOHN DAVID VP and GM Cell Therapy
X
LAPOINTE ANTHONY GREGG Director
X
Marino Mark Chief Medical Officer
X
HAYDEN JEREMY B. General Counsel & VP of BD
X
MARTELL RON Director
X
HAWRAN PAUL W Director
X
KESTEN STEVEN Exec VP and Chief MO
X
Thompson Tommy G Director
X
Lim Kian Thiam 10% Owner
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-02-14 4 PostFinance AG S D 0.3398 -473,831 4,543,086 1,543,741
2018-02-13 4 PostFinance AG S D 0.3112 -101,710 5,016,917 1,561,265
2018-02-12 4 PostFinance AG S D 0.3148 -185,272 5,118,627 1,611,344
2018-02-09 4 PostFinance AG S D 0.34 -7,552 5,303,899 1,803,326
2018-02-08 4 PostFinance AG S D 0.3431 -228,603 5,311,451 1,822,359
2018-01-11 4 Swissquote Bank SA S D 0.34 -20,000 5,328,229 1,811,598
2018-01-11 4 Swissquote Bank SA S D 0.34 -12,630 5,348,229 1,818,398
2018-01-11 4 Swissquote Bank SA S D 0.3406 -20,000 5,360,859 1,825,909
2018-01-11 4 Swissquote Bank SA S D 0.3405 -20,000 5,380,859 1,832,182
2018-01-10 4 Swissquote Bank SA S D 0.3803 -15,796 5,400,859 2,053,947
2018-01-09 4 Swissquote Bank SA S D 0.3902 -20,000 5,416,655 2,113,579
2018-01-09 4 Swissquote Bank SA S D 0.3964 -20,000 5,436,655 2,155,090
2018-01-09 4 Swissquote Bank SA S D 0.38 -20,000 5,456,655 2,073,529
2018-01-09 4 Swissquote Bank SA S D 0.38 -20,000 5,456,655 2,073,529
2018-01-09 4 Swissquote Bank SA S D 0.37 -20,000 5,496,655 2,033,762
2016-08-10 4 HARRIS JOHN DAVID P D 2.03 2,500 7,000 14,210
2016-06-15 4 LYONS GARY A By Trust X I 1,900 4,358
2016-06-14 4 RICKEY DAVID By Trust P I 2.10 5,000 73,230 153,783
2016-06-15 4 RICKEY DAVID By Trust X I 16,000 71,226
2016-06-15 4 RICKEY DAVID By Charitable Trust X I 6,000 24,004
2016-06-15 4 HEDRICK MARC H By Family Trust X I 41,305 83,133
2016-06-14 4 Naughton Gail K P D 2.10 1,000 2,400 5,040
2016-06-15 4 Hawkins Richard J X D 3,356 8,435
2016-06-15 4 Girao Tiago X D 5,667 14,084
2016-06-15 4 HAYDEN JEREMY B. X D 1,896 3,643
2016-06-15 4 KESTEN STEVEN X D 200 3,881
2016-06-15 4 HARRIS JOHN DAVID X D 2,500 4,500
2016-05-13 4 HARRIS JOHN DAVID P D 2.71 2,000 2,000 5,420
2016-03-09 4 RICKEY DAVID By Charitable Trust P I 0.1886 50,000 1,023,444 193,022
2016-03-09 4 RICKEY DAVID By Trust P I 0.1886 100,000 1,023,444 193,022
2016-01-28 4 KESTEN STEVEN A D 47,000 55,201
2016-01-28 4 Girao Tiago A D 35,250 123,250
2016-01-28 4 HEDRICK MARC H A D 70,500 627,411
2015-09-03 4 Thompson Tommy G By LLC P I 0.3745 25,449 83,600 31,308
2015-09-02 4 HAYDEN JEREMY B. P D 0.355 8,200 26,200 9,301
2015-08-28 4 RICKEY DAVID By Trust P I 0.3148 21,000 653,385 205,686
2015-08-28 4 RICKEY DAVID By Charitable Foundation P I 0.3148 35,000 220,059 69,275
2015-08-28 4 HEDRICK MARC H By Family Trust P I 0.31 1,200 556,911 172,642
2015-08-27 4 HEDRICK MARC H By Family Trust P I 0.3052 10,000 555,711 169,603
2015-08-27 4 RICKEY DAVID By Trust P I 0.2992 50,000 632,385 189,210
2015-08-26 4 RICKEY DAVID By Trust P I 0.327 25,000 582,385 190,440
2015-08-21 4 HEDRICK MARC H By Family Trust P I 0.35 5,000 545,711 190,999
2015-08-21 4 RICKEY DAVID By Trust P I 0.375 50,000 557,385 209,019
2015-08-21 4 HEDRICK MARC H By Family Trust P I 0.38 5,000 540,711 205,470
2015-08-19 4 HAYDEN JEREMY B. P D 0.392 18,000 18,000 7,056
2015-08-20 4 HEDRICK MARC H By Family Trust P I 0.40 9,700 535,711 214,284
2015-08-20 4 HEDRICK MARC H By Family Trust P I 0.399 300 526,011 209,878
2015-08-19 4 RICKEY DAVID By Trust P I 0.3934 48,600 507,385 199,605
2015-08-19 4 KESTEN STEVEN By Family Trust P I 0.3871 6,000 8,201 3,175
2015-08-18 4 HEDRICK MARC H By Family Trust P I 0.395 9,900 525,711 207,656
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)
CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Cytori Therapeutics Inc (CYTX) CEO Marc Hedrick on Q2 2018 Results - Earnings Call Transcript

2018-08-15 seekingalpha
Good afternoon, ladies and gentlemen. Welcome to the Cytori Therapeutics Second Quarter 2018 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be opened for your questions following the presentation. [Operator Instructions]

Your Daily Pharma Scoop: IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish

2018-07-11 seekingalpha
Note: ISR has a market cap of less than $100mn and trades below $1. These stocks are inherently risky, and we do not invest in such stocks. However, on Monday, on this news, the stock went above $1, which is when we covered it. (53-6)

Cytori Therapeutics Erectile Dysfunction Stem Cell Therapy Shows Positive Results in Early Trial

2018-07-09 biospace
Cytori Therapeutics, headquartered in San Diego, published data from its clinical trial of Adipose-Derived Regenerative Cells (ADRCs) in the journal Urology showing positive results.

Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good afternoon, ladies and gentlemen. Welcome to Cytori Therapeutics First Quarter 2018 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be opened for questions following the presentation. [Operator Instructions] (25-1)

BRIEF-Cytori Therapeutics - Co Met With U.S. FDA To Discuss Outcome Of Star Clinical Trial

2018-03-16 reuters
* CYTORI THERAPEUTICS - ON MARCH 1, CO MET WITH U.S. FDA TO DISCUSS OUTCOME OF STAR CLINICAL TRIAL AND CO’S PLANS FOR HABEO CELL THERAPY - SEC FILING (25-0)